Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.

British journal of cancer - 9 Sept 2002

van Hattum A H, Hoogsteen I J, Schlüper H M M, Maliepaard M, Scheffer G L, Scheper R J, Kohlhagen G, Pommier Y, Pinedo H M, Boven E

Abstract excerpt

DX-8951f (exatecan mesylate), a new water-soluble derivative of camptothecin, is currently being evaluated in phase II clinical trials. Resistance may be acquired when treating cancer patients with DX-8951f. Therefore, we selected a subline of the human ovarian cancer cell line A2780 for resistance against DX-8951f to investigate possible mechanisms of resistance. This DX-8951f-resistant subline, designated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to DNA Topoisomerases, Type I

Share to Isoquinolines

Share to Neoplasms, Experimental

Share to Tetrazolium Salts

Share to Topoisomerase I Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 12237778
DOI: 10.1038/sj.bjc.6600508
PMCID: PMC2364245

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.PMID 12237778Read ↗

Mechanisms of Cellular Resistance to CamptothecinsSemantic proximity Read ↗

Drug resistance in hematologic malignanciesSemantic proximity Read ↗

Prediction of Broad Spectrum Resistance of Tumors towards Anticancer DrugsSemantic proximity Read ↗

Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expressionSemantic proximity Read ↗

Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.Semantic proximity Read ↗

Characterization of SN38-Resistant T47D Breast Cancer Cell Sublines Overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4Semantic proximity Read ↗

Mechanisms of Resistance to CabazitaxelSemantic proximity Read ↗

Drug resistance reversal--are we getting closer?Semantic proximity Read ↗

CG5/Dx human breast cancer cell line: characterization of a new doxorubicin-resistant variant.Semantic proximity Read ↗

DX-8951F, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variantSemantic proximity Read ↗

Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.Semantic proximity Read ↗

Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.